On first glance, Globus Medical (GMED) looks like it could be one of the unicorns of the med-tech space - a legit growth story that the market hasn't already pushed up to a red-hot valuation. Globus has what seems to be a sustainable culture built around product innovation, and that steady stream of innovative products could be just the ticket for success in a price-constrained implant world. That said, valuation isn't quite the slam-dunk that value investors may hope to see.
As We Knew, Globus Did Well At The End Of 2012
Between the earlier release of Q4 revenue numbers and the results we've seen from other major spine companies like Johnson & Johnson (JNJ), Medtronic...
Only subscribers can access this article, which is part of the PRO research library covering 3,580 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: